Clinical trial
RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease
NCT01868009 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease
- Lead sponsor
- GlaxoSmithKline
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 31, 2013
- Completion date
- July 31, 2013
- Enrollment
- 287 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.